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date of the subjects with the disease. Hourly productivity was units produced per hour
worked during the year. Annual productivity was total units produced during the year.
Incremental productivity  adjusted differences between the disease cohort and the 
controls and considered signiﬁ cant at P a 0.05. RESULTS: Employees with productiv-
ity eligibility for the disease/controls were: BPD 59/27,574; OMD 1,382/25,268; CC 
82/27,276; FD 73/27,513; GERD 541/26,775; gout 86/27,472; and insomnia
415/26,240. Hourly productivity results (incremental units per hour worked; percent
disease/control; signiﬁ cance) were: CC (1.26; 106.6%; P  0.05); insomnia (0.46;
102.5%; P  0.05), OMD (0.41; 102.0% P  0.05), GERD (0.849; 95.6%; P 
0.0481), gout (0.65; 96.5%; P  0.05), BPD (1.35; 93.5%; P  0.05); and FD (1.73;
90.8%; P  0.05). Annual productivity results (incremental units per year; percent 
disease/control; signiﬁ cance) were: GERD (1754; 94%; P  0.0391), OMD (414; 
101.2%; P  0.05); CC (194; 100.7%; P  0.05); gout (566; 98.0%; P  0.05), 
insomnia (925; 96.8%; P  0.05), FD (3,022; 89.1%; P  0.05); and BPD (7,103; 
79.9%; P  0.0001). CONCLUSIONS: Employees with GERD have signiﬁ cant
decreases in both annual and hourly productivity. Employees with BPD experienced
a signiﬁ cant decrease in annual productivity but not in hourly productivity. Many
comparisons were not signiﬁ cant, which contradicts some self reported data indicating
impairment due to the conditions.
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OBJECTIVES: The productivity costs of intimate partner violence (IPV) have received
considerable attention by human resource experts, employers and news outlets, includ-
ing the BBC and Washington Post. Absences, tardiness and turnover have been esti-
mated. Yet, validated estimates of “presenteeism” (functioning at work) are unknown. 
METHODS: In 2007, 190 female IPV victims petitioning a US court for orders for 
protection (OP) consented to participate in a randomized control trial which included 
the validated Work Limitations Questionnaire, the SF-12v2, the CES-D (for depression
and anxiety), the CTS2S and the Danger Assessment. The WLQ is sensitive to changes
in depression and anxiety over time and to a variety of medical and behavioral health 
conditions. We report descriptive statistics and univariate comparisons of working and 
non-working subjects using the WLQ. The paper will include multivariate analyses 
controlling for mental health and overall health status, neighborhood poverty rates 
and household characteristics, and comparisons among scales of speciﬁ c domains 
(time management, mental/social performance, physical, output). The sample is com-
prised of 122 subjects who completed time two assessments. RESULTS: Employed 
subjects report a mean WLQ Productivity Loss Score of 94.3 (range 75.13–100; s.d. 
6.28), representing a performance loss while working, of 5.7% (or 4.6 hours over 2
weeks of full-time employment) compared to the healthy worker norm. Employed
women (n  75) reported better health, less danger, and less severe mental health 
symptoms than those outside of the workforce (n  47) at the time of their OP Peti-
tions. CONCLUSIONS: To our knowledge, these are the ﬁ rst estimates of work loss
reported by IPV victims. When considered on a continuum of burden of illness due
to work productivity loss, preliminary data suggest this population has a greater 
burden of illness than breast cancer survivors, but a lower burden than employees
with active major clinical depression.
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THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION
AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT 
PREVIOUS DRUG COVERAGE
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OBJECTIVES: To examine, using nationally representative data, the impact of Medi-
care Part D on medication utilization, out-of-pocket-costs, non-drug medical service 
utilization, and health outcomes among civilian non-institutionalized Medicare beneﬁ -
ciaries without prescription drug coverage prior to the implementation of Medicare 
Part D. METHODS: The primary data were from the Medical Expenditure Panel 
Survey (MEPS) panel 10 data and the corresponding 2005 and 2006 pharmacy com-
ponent data. This study included Medicare beneﬁ ciaries between 65 and 79 years old 
that had only Medicare Fee for Service (FFS) in 2005. Patients between 55 and 63 
years old with no drug coverage in 2005 served as control subjects. Difference-in-dif-
ferences was used to identify the effects of Medicare Part D on health care utilization,
expenditures, non-drug medical service utilization, and health outcomes among Medi-
care beneﬁ ciaries. RESULTS: The mean amount paid by the near elderly without 
insurance in 2005 declined 7.8%, while the mean amount paid by Medicare beneﬁ -
ciaries with Medicare FFS only in 2005 decreased 40.6%. The number of prescription 
reﬁ lls of the near elderly increased 10.35%, while there was only 4.3% increase among
the Medicare beneﬁ ciaries. ER visits among the Medicare FFS group declined 2.6%, 
while the number of ER visits among the near elderly increased 0.94%. There was 
only small growth rate difference in other outcomes variable. CONCLUSIONS: Evi-
dence from the MEPS data set suggests that Medicare Part D reduced out of pocket 
costs, drug utilization, and ER visits among patients without prior coverage. While 
cost reduction was expected, the reduction in utilization of drugs was not. Future 
research should further examine these trends.
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MANDATE
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Excellus BlueCross BlueShield, Rochester, NY, USA
OBJECTIVES: To estimate the proportion of all very-low and moderately-low-birth-
weight (VLBW, MLBW) infants and the short-term costs associated with fertility 
therapy in an insured population with a state mandate that requires coverage for fertil-
ity drugs but not in vitro fertilization (IVF) or drugs used with IVF. METHODS: The 
study sample consists of all live births, 2003–2007, that could be linked to mothers
with continuous pharmacy and medical beneﬁ ts eligibility during the 11 months before
delivery, within a geographically deﬁ ned subset of a commercially insured population. 
Likely causal relationships with fertility therapy are deduced and categorized as clo-
miphene or follicle-stimulating hormone (FSH) / intrauterine insemination (IUI) or 
IVF, based on the intervals between the dates of delivery and claims for IUI, clomi-
phene, FSH, or embryo transfer. Birthweight is categorized from claims coding. Mater-
nal and infant claims charge distributions are characterized. RESULTS: Of 31,708 live 
births from 30,905 deliveries by 27,195 distinct women, clomiphene, FSH, and FSH 
 IVF categories respectively account for 4.2%, 2.8%, 0.7% of the total number;
8.9%, 16.4%, 3.9% of all VLBW; 8.7%, 12.1%, 3.5% of all MLBW. Mean infant
charges during the 12 months after birth were not signiﬁ cantly different from other 
infants in the same birthweight categories. Mean charges during ﬁ rst 12 months for
all VLBW, MLBW, and other infants were, respectively, $248,600, $33,560, $6,990, 
and low-birthweight infants collectively accounted for 41.6% of all claims charges
for infants. Differences in mean maternal charges are explained by fertility therapy, 
Caesarian section, and multiple gestation. CONCLUSIONS: Analysis of administra-
tive claims data can supplement IVF registry data and published single or multicenter
studies to inform models that predict outcomes and costs associated with different 
policy choices.
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OBJECTIVES: Japanese version of Beers criteria (JP-BC) for potentially inappropriate 
medications in elderly patients was developed by consensus among nine specialists in
order to reﬂ ect regional medical practice and available medications. The prevalence of, 
and risk factors and medical costs associated with JP-BC were examined. METHODS:
A cross-sectional study was conducted using health insurance claims data in Japan. 
Patients aged 65 years or older and had a pharmacy claim between October 2006 and
September 2007 were selected and the use of JP-BC was identiﬁ ed. Associations with
patient demographics, health care utilization patterns and co-morbidities were assessed 
using logistic regression models. Medical costs associated with the JP-BC were also
examined using generalized linear models. RESULTS: Among 6991 old patients, 
41.2% were used one of the JP-BC. Commonly used medications were H2 blockers
(19.5%), benzodiazepines (10.9%) and anticholinergics and antihistamines (7.8%).
Patients with multiple medications, long-term inpatient care and multiple chronic
conditions including gastrointestinal and cardiovascular diseases were more likely to 
use JP-BC. Mean annual cost for JP-BC users was 517,516 yen (5,625 US$), which 
was 2.4 times higher than that in non JP-BC users. Cost differences were still observed
after risk adjustment using Charlson or Elixhauser co-morbidities. High medical costs 
among JP-BC users were partly explained by their high likelihood of multiple medica-
tions and long-term inpatient care. CONCLUSIONS: The prevalence of potentially 
inappropriate medication use in Japan was relatively higher than those previously 
reported in other countries even though regional speciﬁ c medications were considered. 
Drug utilization reviews using the criteria must be promoted to increase awareness of 
inappropriate pharmaceutical cares among elderly and control medical costs.
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OBJECTIVES: The Medicare Part D prescription drug beneﬁ t was introduced for 
Medicare enrollees to obtain prescription drug coverage. The 2006 beneﬁ t did not
provide insurance coverage for standard prescription drug plan (PDP) members who 
incurred prescription costs between $2250 and $3600 dollars (referred to as the 
“doughnut hole”). We evaluated whether the “doughnut hole” was a factor in altering
the prescription fulﬁ llment decisions of Part D members. METHODS: In the current 
retrospective cohort study, 750 pharmacy adjudication records from a national Part
D HMO pharmacy database were investigated for the year 2006. Five hundred par-
ticipants (standard PDP members) without coverage in the doughnut hole were com-
pared to a group of 250 participants (enhanced PDP members) whose prescription
coverage did not lapse in the doughnut hole. All participants were analyzed via a 
multivariate strategy for their prescription fulﬁ llment decisions which were recorded
as an endpoint of ﬁ lling, delaying, switching, or stopping their respective medication. 
RESULTS: From 72% of the standard PDP members who experienced the doughnut 
hole and altered their prescription decision, it was determined that 22% delayed
